Skip to main content
. 2023 Apr 16;11(4):852. doi: 10.3390/vaccines11040852

Table 6.

No. and type of intramuscularly delivered vaccines as booster doses and no. of angioedema attacks following the vaccination (≤72 h).

Total BNT162b2 mRNA-1273
No. of vaccination doses (%) 124 (100%) 82 (66%) 42 (34%)
No. of angioedema attacks (≤72 h) 18 (100%) 9 (50%) 9 (50%)